AB InBev: The interim is back. Arcadis: Slow return to organic growth, FCF disappoints. Ayvens: Keeping its promise. dsm-firmenich: Waiting for Godot. D'Ieteren: Boyd prelim 3Q25, $1.3bn M&A deal, NYSE listing, $780m capital increase. Flow Traders: Down but not out. Ontex: FY25F guidance confirmed despite a modestly softer 3Q25. Recticel: Weak 3Q25 but comforting outlook. Shell plc: Solid story with cash continuing to come in strongly. TKH Group: Preview - subsea remains in foc...
argenx' 3Q25 numbers came in solid with Vyvgart sales of $ 1.13b, delivering another beat (approx. 6.8%) on company compiled CSS ($ 1,054.8m). Product revenue consensus for FY25 currently stands at $ 3.93b, which is well within reach as PFS continues to contribute to the launch momentum. argenx reached operating profitability for the 5th consecutive quarter despite a 40% increase in opex. ACCUMULATE maintained.
3Q volumes decreased by 3.7% organically which was below our and consensus forecasts, while organic adj EBITDA growth of +3.3% outperformed consensus (of +0.9%). ABI reiterated FY25 guidance of 4-8% organic EBITDA growth which is in line with the mid term guidance. Importantly, a $ 6bn share buyback (over 24 months) was announced (as well as a € 0.15 dividend). We still see ABI as the undisputed leader in the beer space, with leading market shares in many markets, ongoing digitization and premiu...
argenx Reports Third Quarter 2025 Financial Results and Provides Business Update $1.13 billion in third quarter global product net sales On track to submit seronegative gMG sBLA by year-end and report ADAPT-OCULUS results in 1H26 – supporting pursuit of broadest MG label of any biologic Five registrational study readouts expected in 2026 from leading immunology pipeline Management to host conference call today at 1:30 PM CET (8:30 AM ET) October 30, 2025 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving th...
argenx Presents New Data at AANEM and MGFA Highlighting the Strength and Broad Benefit of VYVGART for Myasthenia Gravis Patients VYVGART demonstrated clinically meaningful benefit across all AChR-Ab seronegative gMG subtypes in ADAPT SERON, supporting broad role of pathogenic IgGs in disease activityFinal ADAPT SC+ results show ~60% of VYVGART gMG patients achieved minimal symptom expression (MSE), with 88% sustaining MSE for at least 4 weeks Real world data show >70% of patients treated with VYVGART meaningfully reduced glucocorticoid use while maintaining clinical benefit October 29, ...
A director at Atenor SA bought 34,101 shares at 2.990EUR and the significance rating of the trade was 60/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...
Participation notification by Morgan Stanley Press release Regulated information Brussels, October 27, 2025, 17:45 CET In line with Belgian transparency legislation (Law of May 2, 2007), Morgan Stanley recently sent to Solvay the following transparency notification indicating that they crossed the threshold of 3%. Here is a summary of the notification: Date on which the threshold was crossed Voting rights after the transaction Equivalent financial instruments after the transaction Total October 16, 2025 / / / The ...
Notification de participation par Morgan Stanley Communiqué de presse Information réglementée Bruxelles, le 27 octobre 2025 - 17h45 CET Conformément à la législation et réglementation en matière de transparence financière (loi du 2 mai 2007), Morgan Stanley a envoyé récemment à Solvay la notification de transparence suivante, indiquant avoir franchi le seuil de 3%. Voici un résumé de la notification: Date à laquelle le seuil a été franchi Droits de vote après la transaction Instruments financiers équivalents après la tra...
Participatiemelding van Morgan Stanley Persbericht Gereglementeerde informatie Brussel, 27 oktober 2025 - 17u45 CET In overeenstemming met de Belgische transparantiewetgeving (Wet van 2 mei 2007) heeft Morgan Stanley onlangs de volgende transparantiekennisgeving naar Solvay gestuurd om aan te geven dat ze de drempel van 3% heeft overschreden. Hier is een samenvatting van de beweging: Datum van drempeloverschrijding Stemrechten na de transactie Aan stemrechten gelijkgestelde financiële instrumenten na de transactie Totaa...
Allfunds Group PLC: 3Q25 Preview. Ahold Delhaize: Amazon to invest €1.4bn in the Netherlands. ASM International: 3Q25 preview – derisked estimates. Basic-Fit: Acquires low-cost franchise operator Clever Fit; now Germany market leader. JDE Peet's: Ad hoc progress update. Lotus Bakeries: Product recall for waffles in Belgium. Melexis: 3Q25 preview, slow cyclical recovery
Merus announced interim clinical data (29 July 2025 cutoff) from the ongoing phase 2 trial of petosemtamab (EGFR x LGR5 bispecific antibody) + standard of care FOLFOX/FOLFIRI (chemo) in 1L, 2L metastatic CRC (mCRC) and petosemtamab monotherapy in 3L+ mCRC. The results were presented at the AACR-NCI-EORTC, and confirm and build upon the responses reported from an initial dataset with a previous cut-off date (28 April 2025). We view the numbers as competitive vs. cetuximab (EGFR antibody) + FOLFOX...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.